Virginie Lafont

TL;DR: The feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies is demonstrated by 18F-BMS-986192, which bound to tumor tissues as a function of PD- L1 expression determined by immunohistochemistry.

TL;DR: Results indicate specific biodistribution to the spleen, which can be blocked by co-administration of excess nivolumab, and distribution to other organs is consistent with elimination pathways of antibodies, with primary clearance through the liver.

TL;DR: Adnectin–drug conjugates are presented, an alternative platform for tumor-specific delivery of cytotoxic payloads and its high thermostability, its localization to target-expressing tumor cells in vitro and in vivo, its fast clearance from normal tissues and its efficacy against Glypican-3-positive mouse xenograft models.

TL;DR: In this paper, novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics, are presented, and compared.

TL;DR: This assay appears to specifically measure total sPD-1 protein since the human anti- PD-1 antibody, nivolumab, and the endogenous ligands of PD- 1 protein, PDL-1 and PDL,2, do not interfere with the assay.